Isolation, expansion and use of clonogenic endothelial progenitor cells
A hierarchy of endothelial colony forming cells (EPCs) was identified from mammalian cord blood, umbilical vein and aorta. A newly isolated cell named high proliferative potential-endothelial colony forming cell (HPP-ECFC) was isolated and characterized. Single cell assays were developed that test the proliferative and clonogenic potential of endothelial cells derived from cord blood, or from HUVECs and HAECs. EPCs were found to reside in vessel walls. Use of a feeder layer of cells derived from high proliferative potential-endothelial colony forming cells (HPP-ECPCS) from human umbilical cord blood, stimulates growth and survival of repopulating hematopoietic stem and progenitor cells. Stimulation of growth and survival was determined by increased numbers of progenitor cells in in vitro cultures and increased levels of human cell engraftment in the NOD/SCID immunodeficient mouse transplant system.
1. A culture method for a high proliferative potential-endothelial colony forming cell (HPP-ECFC), the method comprising:
(a) providing a blood sample selected from the group consisting of umbilical cord blood and blood vessel blood;
(b) isolating a mononuclear cell from the blood sample;
(c) seeding the mononuclear cell on a culture substrate, wherein the culture substrate comprises a coating comprising an extracellular matrix molecule (ECM);
(d) culturing the seeded adherent mononuclear cell in a culture medium for about 5 to about 10 days to form a colony comprising cells;
(e) immunophenotyping the cells from the colony to determine expression of CD31, CD141, CD105, CD146, CD144, vWF, and flk-1, but not CD45 and CD14; and
(f) culturing the cells that express CD31, CD141, CD105, CD144, CD146, vWF, and flk-1, but do not express CD45 and CD14, wherein the cells have a nuclear diameter ranging from 8 microns to 10 microns.
2. The method of claim 1 further comprising subculturing the cells that express CD31, CD141, CD105, CD146, CD144, vWF, and flk-1, but not CD45 and CD14 for at least 30 population doublings.
3. The method of claim 1 further comprising subculturing a single cell that expresses CD31, CD141, CD105, CD146, CD144, vWF, and flk-1, but not CD45 and CD14 on an ECM coated plate to form a secondary colony comprising at least 2000 cells.
4. The method of claim 3 , further comprising subculturing a single cell of the secondary colony on an ECM coated plate to form a tertiary colony.
5. The method of claim 1 , wherein the culture medium comprises complete EGM-2 media.
6. The method of claim 1 , wherein the extracellular matrix molecule is type I collagen.
7. The method of claim 1 further comprising analyzing the cells that express CD31, CD141, CD105, CD146, CD144, vWF, and flk-1, but not CD45 and CD14 for ingestion of acetylated-low density lipoprotein.
8. The method of claim 1 , wherein the number of cells increases about 10 20 fold over a period of 100 days in culture.
9. The method of claim 1 , further comprising transducing the cells that express CD31, CD141, CD105, CD144, CD146, vWF, and flk-1, but do not express CD45 and CD14 with a nucleic acid encoding a marker.
10. The method of claim 9 , wherein the marker is green fluorescent protein.
11. The method of claim 9 , further comprising selecting a single cell expressing the nucleic acid encoding the marker.
12. The method of claim 11 , wherein the single cell expressing the nucleic acid encoding the marker is plated.
13. The method of claim 12 , wherein the single cell expressing the nucleic acid encoding the marker is plated by fluorescent cytometry sorting.
14. The method of claim 12 , wherein the single cell expressing the nucleic acid encoding the marker forms a secondary colony comprising at least 2000 cells.
15. The method of claim 14 , further comprising subculturing a single cell of the secondary colony on an ECM coated plate to form a tertiary colony.